Abstract
BackgroundAdalimumab (ADA) has been shown to be safe and effective in patients (pts) with long-standing rheumatoid arthritis (RA).1 Patients with RA are candidates for routine vaccination with inactivated agents, in...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
